ZyVersa Therapeutics reported a Q3 2024 net loss of $2.4M, showing a 17.3% improvement from $2.9M loss in Q3 2023. Research and development expenses decreased 35.3% to $0.4M, while general and administrative expenses fell 17.7% to $1.8M. The company held $0.1M in cash as of September 30, 2024, requiring additional financing for continued operations.The company plans to initiate a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in Q1 2025, with initial data expected mid-2025. Additionally, ZyVersa formed a new Obesity Scientific Advisory Board and plans two proof-of-concept studies for IC 100 in obesity models, with at least one study starting in Q4 2024. An IND submission for IC 100 is targeted for Q2 2025, followed by Phase 1 trials.ZyVersa raised approximately $3.9M from the beginning of Q3 2024 to present. The company's pipeline includes IC 100 for obesity and metabolic complications, and VAR 200 for kidney diseases, with a total accessible market exceeding $100B.

ZyVersa Therapeutics reported a Q3 2024 net loss of $2.4M, showing a 17.3% improvement from $2.9M loss in Q3 2023. Research and development expenses decreased 35.3% to $0.4M, while general and administrative expenses fell 17.7% to $1.8M. The company held $0.1M in cash as of September 30, 2024, requiring additional financing for continued operations.The company plans to initiate a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in Q1 2025, with initial data expected mid-2025. Additionally, ZyVersa formed a new Obesity Scientific Advisory Board and plans two proof-of-concept studies for IC 100 in obesity models, with at least one study starting in Q4 2024. An IND submission for IC 100 is targeted for Q2 2025, followed by Phase 1 trials.ZyVersa raised approximately $3.9M from the beginning of Q3 2024 to present. The company's pipeline includes IC 100 for obesity and metabolic complications, and VAR 200 for kidney diseases, with a total accessible market exceeding $100B.